| Item Type | Name |
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
|
Concept
|
Drug Therapy, Combination
|
|
Concept
|
Chemotherapy, Adjuvant
|
|
Concept
|
Induction Chemotherapy
|
|
Concept
|
Maintenance Chemotherapy
|
|
Academic Article
|
Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support.
|
|
Academic Article
|
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
|
|
Academic Article
|
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
|
|
Academic Article
|
A phase I study of liposomal doxorubicin (Doxil) with topotecan.
|
|
Academic Article
|
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
|
|
Academic Article
|
Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies.
|
|
Academic Article
|
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.
|
|
Academic Article
|
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
|
|
Academic Article
|
Chemotherapy in endometrial cancer.
|
|
Academic Article
|
Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies.
|
|
Academic Article
|
Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804.
|
|
Academic Article
|
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
|
|
Academic Article
|
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
|
|
Academic Article
|
An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases.
|
|
Academic Article
|
Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics.
|
|
Academic Article
|
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
|
|
Academic Article
|
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.
|
|
Academic Article
|
Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer.
|
|
Academic Article
|
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Phase I trial of concomitant chemoradiotherapy for cervical cancer and other advanced pelvic malignancies.
|
|
Academic Article
|
Absence of major peripheral neuropathy in a phase II trial of ifosfamide with vinorelbine in patients with ovarian cancer previously treated with platinum and paclitaxel.
|
|
Academic Article
|
Adjuvant aromatase inhibitors: are we there yet?
|
|
Academic Article
|
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
|
|
Academic Article
|
A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Gemcitabine/docetaxel--welcome to a new standard.
|
|
Academic Article
|
The impact of sharing results of a randomized breast cancer clinical trial with study participants.
|
|
Academic Article
|
Phase I trial of concomitant vinorelbine, paclitaxel, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies.
|
|
Academic Article
|
Re: Response of aleukemic granulocytic sarcoma to all-trans-retinoic acid plus interferon alfa-2a.
|
|
Academic Article
|
Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab.
|
|
Academic Article
|
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.
|
|
Academic Article
|
The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.
|
|
Academic Article
|
Intraperitoneal chemotherapy for ovarian cancer.
|
|
Academic Article
|
Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Major progress for a less common cancer.
|
|
Academic Article
|
Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
|
|
Academic Article
|
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
|
|
Academic Article
|
Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study.
|
|
Academic Article
|
A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.
|
|
Academic Article
|
Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study.
|
|
Academic Article
|
Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant.
|
|
Academic Article
|
Management of advanced-stage and recurrent endometrial cancer.
|
|
Academic Article
|
Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study.
|
|
Academic Article
|
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
|
|
Academic Article
|
Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study.
|
|
Academic Article
|
The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
|
|
Academic Article
|
Chemo- and radiotherapy in adjuvant management of optimally debulked endometrial cancer.
|
|
Academic Article
|
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.
|
|
Academic Article
|
Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group Study.
|
|
Academic Article
|
Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer.
|
|
Academic Article
|
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
|
|
Academic Article
|
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
|
|
Academic Article
|
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
|
|
Academic Article
|
Neo-adjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): efficacy and safety in a phase II feasibility study.
|
|
Academic Article
|
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.
|
|
Academic Article
|
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.
|
|
Academic Article
|
Gene expression of peripheral blood cells reveals pathways downstream of glucocorticoid receptor antagonism and nab-paclitaxel treatment.
|
|
Academic Article
|
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
|
|
Academic Article
|
Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.
|
|
Academic Article
|
Nanomedicine for Combination Therapy of Cancer.
|
|
Academic Article
|
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
|
|
Academic Article
|
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
|
|
Academic Article
|
Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
|
|
Academic Article
|
Second-Line Therapy for Endometrial Cancer: The Need for Better Options.
|
|
Academic Article
|
Chemotherapy-induced peripheral neuropathy: Current status and progress.
|
|
Academic Article
|
Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy.
|
|
Academic Article
|
Adjuvant ovarian suppression in premenopausal breast cancer.
|
|
Academic Article
|
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
|
|
Academic Article
|
Adjuvant ovarian suppression in premenopausal breast cancer.
|
|
Academic Article
|
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.
|
|
Academic Article
|
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
|
|
Academic Article
|
Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings.
|
|
Academic Article
|
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
|
|
Academic Article
|
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.
|
|
Academic Article
|
High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.
|
|
Academic Article
|
High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer.
|
|
Academic Article
|
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
|
|
Academic Article
|
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
|
|
Academic Article
|
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.
|
|
Academic Article
|
A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.
|
|
Academic Article
|
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
|
|
Academic Article
|
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
|
|
Academic Article
|
Comparison of the incidence of febrile neutropenia in obese and normal weight breast cancer patients receiving myelosuppressive chemotherapy and prophylactic pegfilgrastim.
|
|
Academic Article
|
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
|
|
Academic Article
|
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
|
|
Academic Article
|
Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows.
|
|
Academic Article
|
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
|
|
Academic Article
|
Current recommendations and recent progress in endometrial cancer.
|
|
Academic Article
|
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
|
|
Academic Article
|
Uterine Cancer: Adjuvant Therapy and Management of Metastatic Disease.
|
|
Academic Article
|
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
|
|
Academic Article
|
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
|
|
Academic Article
|
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
|
|
Academic Article
|
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.
|
|
Academic Article
|
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).
|
|
Academic Article
|
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
|
|
Academic Article
|
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.
|
|
Academic Article
|
Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer.
|
|
Academic Article
|
Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer.
|
|
Academic Article
|
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
|
|
Academic Article
|
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
|
|
Academic Article
|
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors.
|
|
Academic Article
|
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
|
|
Academic Article
|
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
|
|
Academic Article
|
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
|
|
Academic Article
|
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
|
|
Academic Article
|
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
|
|
Academic Article
|
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.
|
|
Academic Article
|
Flashback Foreword: Concurrent Chemotherapy/Radiotherapy for Cervical Cancer.
|
|
Academic Article
|
Validation of the RSClin risk calculator in the National Cancer Data Base.
|